6,179 Shares in Medtronic PLC $MDT Purchased by Investment Research Partners LLC

Investment Research Partners LLC purchased a new stake in Medtronic PLC (NYSE:MDT) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,179 shares of the medical technology company’s stock, valued at approximately $567,000.

Several other hedge funds have also bought and sold shares of MDT. State Street Corp grew its stake in shares of Medtronic by 1.0% during the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company’s stock worth $5,800,550,000 after purchasing an additional 625,992 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Medtronic by 0.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company’s stock valued at $2,044,637,000 after purchasing an additional 192,410 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company’s stock valued at $2,008,278,000 after purchasing an additional 98,220 shares during the period. Invesco Ltd. boosted its holdings in Medtronic by 3.9% during the second quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock worth $1,538,302,000 after buying an additional 666,557 shares in the last quarter. Finally, Norges Bank purchased a new stake in Medtronic during the second quarter worth $1,432,698,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, March 1st. UBS Group reissued a “neutral” rating and set a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Leerink Partners restated an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research report on Tuesday, March 10th. Royal Bank Of Canada lifted their price target on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Finally, William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $110.74.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT opened at $87.17 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock has a market capitalization of $111.92 billion, a PE ratio of 24.28, a P/E/G ratio of 2.27 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a fifty day moving average of $97.29 and a two-hundred day moving average of $96.78.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).